Filtered By:
Drug: Gleevec

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 30 results found since Jan 2013.

Compartmentalized Actions of the Plasminogen Activator Inhibitors, PAI-1 and Nsp, in Ischemic Stroke
In this study, we compare the effects of PAI-1 and Nsp deficiency in a mouse model of ischemic stroke and show that tPA has both beneficial and harmful effects that are differentially regulated by PAI-1 and Nsp. F ollowing ischemic stroke Nsp deficiency in mice leads to larger strokes, increased BBB permeability, and increased spontaneous intracerebral hemorrhage. In contrast, PAI-1 deficiency results in smaller infarcts and increased cerebral blood flow recovery. Mechanistically, our data suggests that these differences are largely due to the compartmentalized action of PAI-1 and Nsp, with Nsp deficiency enhancing tPA act...
Source: Translational Stroke Research - February 4, 2022 Category: Neurology Source Type: research

Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Abstract The relevance of tyrosine kinase inhibitors (TKIs) in the treatment of malignancies has been already defined. Aberrant activation of tyrosine kinase signaling pathways has been causally linked not only to cancers but also to other non-oncological diseases. This review concentrates on the novel plausible usage of this group of drugs in neurological disorders, such as ischemic brain stroke, subarachnoid hemorrhage, Alzheimer's disease, multiple sclerosis. The drugs considered here are representatives of both receptor and non-receptor TKIs. Among them imatinib and masitinib have the broadest spectrum of ther...
Source: Current Neuropharmacology - November 26, 2015 Category: Drugs & Pharmacology Authors: Gagalo I, Rusiecka I, Kocic I Tags: Curr Neuropharmacol Source Type: research

Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis
ConclusionThis phase II study showed that imatinib is safe and tolerable and may reduce neurological disability in patients treated with intravenous thrombolysis after ischaemic stroke. A confirmatory randomized trial is currently underway.
Source: Journal of Internal Medicine - October 31, 2016 Category: Internal Medicine Authors: N. Wahlgren, M. Thor én, B. Höjeberg, T.‐B. Käll, A.‐C. Laska, C. Sjöstrand, J. Höijer, H. Almqvist, S. Holmin, A. Lilja, L. Fredriksson, D. Lawrence, U. Eriksson, N. Ahmed Tags: Original Article Source Type: research

Longitudinal Assessment of Imatinib’s Effect on the Blood–Brain Barrier After Ischemia/Reperfusion Injury with Permeability MRI
Abstract Acute ischemic stroke (AIS) often results in degeneration of the blood–brain barrier (BBB), which can lead to vasogenic edema and an increased risk of intracerebral hemorrhage. Imatinib is an agent that may be able to protect the BBB and reduce the risk of the harmful consequences of BBB degeneration. We sought to measure the effect of Imatinib on the BBB after experimental stroke longitudinally in vivo with permeability dynamic contrast-enhanced MRI. Ischemia/reperfusion injury was induced with a transient middle cerebral artery occlusion surgery. Rats were given Imatinib at 2 and 20 h after stroke on...
Source: Translational Stroke Research - August 23, 2014 Category: Neurology Source Type: research

Rare Cases of Thrombotic and Embolic Stroke with Hypereosinophilia (P1.295)
Conclusions:Hypereosinophilia can cause both embolic and thrombotic strokes as evidenced by our patients. The etiology of embolic stroke may be due to the direct eosinophilic damage to the endocardium or by the release of eosinophilic basic proteins which initiate endomyocardial necrosis, making the heart a potential source of emboli. Causes of thrombogenicity are multifactorial including the release of tissue factor from specific granules, inactivation of thrombomodulin by binding to the major basic protein, endothelial damage or by elevation of fibrinogen levels. The individual presentations (thrombotic/embolic) will alt...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Finelli, D., Shoamanesh, A., Perera, K. Tags: Cerebrovascular Disease Case Reports I Source Type: research

Vascular PDGFR-alpha protects against BBB dysfunction after stroke in mice
AbstractBlood –brain barrier (BBB) dysfunction underlies the pathogenesis of many neurological diseases. Platelet-derived growth factor receptor-alpha (PDGFRα) induces hemorrhagic transformation (HT) downstream of tissue plasminogen activator in thrombolytic therapy of acute stroke. Thus, PDGFs are attractive therapeutic targets for BBB dysfunction. In the present study, we examined the role of PDGF signaling in the process of tissue remodeling after middle cerebral arterial occlusion (MCAO) in mice. Firstly, we found that imatinib increased lesion size after permanent MCAO in wild-type mice. Moreover, i matinib-induced...
Source: Angiogenesis - September 11, 2020 Category: Molecular Biology Source Type: research

Systematic Review - Combining Neuroprotection With Reperfusion in Acute Ischemic Stroke
ConclusionStudies specifically testing effects of neuroprotective agents in addition to IVT and/or EVT are scarce. Future neuroprotection studies should report standardized functional outcome measures and combine neuroprotective agents with reperfusion therapies in AIS or aim to include prespecified subgroup analyses for treatment with IVT and/or EVT.
Source: Frontiers in Neurology - March 17, 2022 Category: Neurology Source Type: research

Drug Targeting Blood-Brain Barrier 'Hopeful' in Stroke Drug Targeting Blood-Brain Barrier 'Hopeful' in Stroke
Imatinib, a drug that is already available for the treatment of cancer, showed positive results in an initial randomized study in ischemic stroke. Medscape Medical News
Source: Medscape Medical News Headlines - May 26, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Severe paraneoplastic hypoglycemia secondary to a gastrointestinal stromal tumour masquerading as a stroke.
We report the case of a 70-year-old previously healthy female who presented acutely to the Accident and Emergency department with left-sided vasomotor symptoms including reduced muscle tone, weakness upon walking and slurred speech. Physical examination confirmed hemiparesis with VIIth nerve palsy and profound hepatomegaly. A random glucose was low at 1.7 mmol/l, which upon correction resolved her symptoms. In hindsight, the patient recalled having had similar episodes periodically over the past 3 months to which she did not give much attention. While hospitalized, she continued having episodes of symptomatic hypoglycaem...
Source: Diabetes Metab - November 7, 2015 Category: Endocrinology Authors: Dimitriadis GK, Gopalakrishnan K, Rao R, Grammatopoulos DK, Randeva HS, Weickert MO, Murthy N Tags: Endocrinol Diabetes Metab Case Rep Source Type: research

Mortality and Vascular Events Among Elderly Patients with Chronic Myeloid Leukemia (CML): A Retrospective Analysis of Linked Seer-Medicare Data
Conclusions Elderly CML patients had higher mortality and higher rates of MI, stroke, PE and PAD than non-cancer patients. Event rates were not elevated among TKI-treated (primary imatinib) patients, suggesting that VE risk in these CML patients was driven primarily by underlying factors associated with CML. Teaser TKI treatment of CML may be associated with vascular events (VE). We examined event rates and mortality among elderly CML and non-cancer patients using linked cancer registry and Medicare claims data, 2003-2010. CML patients had higher mortality and VE rates. Rates were not elevated among TKI (primarily imatinib...
Source: Clinical Lymphoma Myeloma and Leukemia - February 7, 2016 Category: Cancer & Oncology Source Type: research

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data
Conclusion Elderly patients with CML had greater mortality and greater rates of MI, stroke, PE, and PAD than did noncancer patients. The event rates were not elevated among the TKI-treated (primary imatinib) patients, suggesting that the VE risk in these patients with CML was driven primarily by the underlying factors associated with CML. Micro-Abstract Tyrosine-kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can be associated with vascular events (VEs). We examined the event rates and mortality among elderly patients with and without CML using linked cancer registry and Medicare claims data from 2003 t...
Source: Clinical Lymphoma Myeloma and Leukemia - March 21, 2016 Category: Cancer & Oncology Source Type: research

Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up
CONCLUSIONNilotinib is safe and highly effective in patients with AP-CML, and induces fast and durable responses. More than 50% of patients can achieve MR4.5. Clinical trial.gov: NCT00129740.DisclosuresCortes: novartis: Research Funding. O'Brien: Pfizer: Consultancy, Research Funding; Janssen: Consultancy; Aptose Biosciences Inc.: Consultancy; Kite Pharma: Research Funding; Regeneron: Research Funding; Vaniam Group LLC: Consultancy; Amgen: Consultancy; Pharmacyclics: Consultancy, Research Funding; Celgene: Consultancy; Alexion: Consultancy; Abbvie: Consultancy; GlaxoSmithKline: Consultancy; Acerta: Research Funding; Gilead...
Source: Blood - November 21, 2018 Category: Hematology Authors: Masarova, L., Cortes, J. E., Patel, K. P., O'Brien, S. M., Nogueras Gonzalez, G. M., Konopleva, M. Y., Verstovsek, S., Garcia-Manero, G., Ferrajoli, A., Kadia, T. M., Ravandi, F., Borthakur, G., Dellasala, S. E., Jabbour, E. J., Kantarjian, H. M. Tags: 632. Chronic Myeloid Leukemia: Therapy: Poster II Source Type: research

Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia
CONCLUSION: CP-CML patients treated with different TKIs (ponatinib, bosutinib, imatinib, dasatinib, and nilotinib) did not have different incidence of cardiovascular events (MACE, AOEs, VTEs) in this small cohort of real-world patients with ≥6-month of follow-up. The results were consistent among patients with prior use of one and two TKI types.DisclosuresLevy: Takeda (Millennium Pharmaceuticals, Inc.): Consultancy. Xie: STATinMED Research: Employment. Wang: STATinMED Research: Employment. Neumann: Takeda (Millennium Pharmaceuticals, Inc.): Employment. Srivastava: Takeda (Millennium Pharmaceuticals, Inc.): Employment. N...
Source: Blood - November 21, 2018 Category: Hematology Authors: Levy, M. Y., Xie, L., Wang, Y., Neumann, F., Srivastava, S., Naranjo, D., Zhang, Q., Dalal, M. Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster II Source Type: research

Pharmacological targeting of the PDGF-CC signaling pathway for blood –brain barrier restoration in neurological disorders
Publication date: Available online 12 August 2016 Source:Pharmacology & Therapeutics Author(s): Sebastian A. Lewandowski, Linda Fredriksson, Daniel A. Lawrence, Ulf Eriksson Neurological disorders account for a majority of non-malignant disability in humans and are often associated with dysfunction of the blood–brain barrier (BBB). Recent evidence shows that despite apparent variation in the origin of neural damage, the central nervous system has a common injury response mechanism involving platelet-derived growth factor (PDGF)-CC activation in the neurovascular unit and subsequent dysfunction of BBB integrity. ...
Source: Pharmacology and Therapeutics - August 11, 2016 Category: Drugs & Pharmacology Source Type: research

Neuroprotective effects of an < em > in vitro < /em > BBB permeable phenoxythiophene sulfonamide small molecule in glutamate-induced oxidative injury
Exp Ther Med. 2022 Jan;23(1):79. doi: 10.3892/etm.2021.11002. Epub 2021 Nov 25.ABSTRACTReactive oxygen species (ROS) play a central role in oxidative stress-associated neuronal cell death during ischemia. Further investigation into the inhibition of excessive ROS generation post-stroke is urgently required for the treatment of ischemic stroke. In the present study, the neuroprotective properties of the blood-brain barrier (BBB) penetrant B355227 were investigated. B355227 is a chemical analogue of B355252, and the role of the phenoxythiophene sulfonamide compound B355227 was further investigated in a glutamate-induced oxid...
Source: Experimental and Therapeutic Medicine - December 23, 2021 Category: General Medicine Authors: Smritee Pokharel Nailya S Gliyazova Srinivasa R Dandepally Alfred L Williams Gordon C Ibeanu Source Type: research